Meet Pedro - A Friendly Rectal Microbicide Advocate

Check out this interesting mini-bio of Pedro Goicochea, the latest in IRMA's "Meet a Friendly Rectal Microbicide Advocate" series on the IRMA website here.  Pedro is one of six new bios just posted today, including individuals from Kenya,Thailand and the US.  Each will be featured on the blog, and you can read all of them here right now.




Pedro Goicochea
San Francisco, California

"It took us more than 30 years to realize that there is not one unique strategy to prevent HIV acquisition, and that combination prevention is key, and rectal microbicides must be part of the prevention toolbox."

Originally from Lima, Peru, Pedro is in charge of communications and community relations for the iPrEx OLE study, the open-label continuation of the iPrEx trial. iPrEx is the study that showed daily oral use of the ARV drug Truvada among gay men, other men who have sex with men (MSM), and transgender women worked to prevent HIV.

He enjoys his work because of the invaluable opportunities it provides for him to meet interesting people who are working really hard on finding ways to stop this epidemic. He takes pride in the sensitivity his team shows to community members and for highlighting their needs with scientists and stakeholders. Besides iPrEx OLE, Pedro also just finished a couple of other projects related to the feasibility of voluntary circumcision for HIV prevention in gay men and other MSM, and neonatal male circumcision for HIV prevention, in the jungles of Peru.

In his spare time Pedro loves to ride his bike. He enjoys "having destinations that I reach through the effort of pedaling." Pedro's biggest life influence was his mother, but he is also blessed to be surrounded by excellent people that have been an inspiration. In addition, he has lost several friends to HIV and this motivated him to do something about it.

He was introduced to rectal microbicides and IRMA when he met IRMA chair Jim Pickett through IRMA steering committee member and IRMA-ALC co-founder Jerome Galea. He believes that any strategy to help end the epidemic is useful and thinks that rectal microbicides are an important prevention technology because anal sex is the primary mode of HIV transmission among gay men and other MSM, and that women practice anal sex more than is reported or fully understood.

Pedro has played an important role on the soon-to-be-released IRMA video ("The Rectal Revolution is Here: An Introduction to Rectal Microbicide Clinical Trials") being developed in partnership with the Microbicide Trials Network and Population Council. He is part of the team's Video Advisory Committee and has provided invaluable feedback on content and messaging. He also worked closely on the focus groups (especially those conducted in Lima, Peru) which were designed and implemented to test the "rough cut" of the video with different populations to help ensure the proper messages are coming through. He says it has been a very inspirational expereince and he is really looking forward to see the final release. IRMA plans to release the final version of the video in early September, 2012.

Thanks Pedro, for all that you do!


-------------------
*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.
-------------------

Open-Label Extension of iPrEX HIV PrEP Study Begins at 11 Sites in 6 Countries

Via iPrEX News.

The iPrEx Open-Label Extension Study (iPrEx OLE), the next phase of the first human study to report efficacy results on pre-exposure prophylaxis (PrEP) to prevent HIV infection, has begun at clinical trial sites around the world. Approximately 2,000 men and transgender women who have sex with men are expected to participate in the 72-week iPrEx OLE study. Study sites in the United States and South Africa are enrolling participants now, as other study sites finalize the regulatory approval process.

In PrEP, antiretroviral medications that are usually used to treat HIV are taken by uninfected people to reduce their risk of infection. The iPrEx study found that men and transgender women who have sex with men (MSM) who took a single daily tablet containing the HIV medications emtricitabine and tenofovir (FTC/TDF), known commercially as Truvada®, experienced an average of 44% fewer HIV infections than those who received a placebo (blank pill). HIV infection rates in the iPrEx study dropped by 90% among those who used PrEP consistently enough to have detectable drug in the body. The HIV risk reduction benefits of PrEP were in addition to those provided by safer sex counseling, condoms, HIV testing and the detection and treatment of sexually transmitted infections. iPrEx study results were published in the New England Journal of Medicine in November, 2010.

The news of the start of iPrEx OLE follows the announcements by two other major PrEP studies, Partners PrEP and the CDC study in Botswana, known as TDF2, which demonstrated the safety and efficacy of PrEP in heterosexual women and men.

AdvertisementiPrEx OLE is a continuation of the iPrEx study that will collect additional data on PrEP efficacy, safety and adherence. All HIV-negative participants who took part in the original iPrEx study and who wish to participate will receive FTC/TDF for HIV prevention for 72 weeks through iPrEx OLE. No placebo will be used in the Open Label Extension.

"We are in a critical moment in HIV prevention research," said iPrEx Protocol Chair Robert Grant, MD, MPH of the Gladstone Institutes and the University of California at San Francisco. "iPrEx provided the first proof of an important new method of HIV prevention that can help slow the global toll of 2.6 million new HIV infections each year. Partners PrEP and the TDF2 study have now expanded that finding by demonstrating the effectiveness of PrEP in heterosexual women and men. Developing and deploying proven HIV prevention methods -- including PrEP, microbicides, vaginal gels, clean needles, medical male circumcision, early treatment, counseling, testing, condoms and suppressive therapy for pregnant women will all be key to slowing the global epidemic."

Read the rest here.

[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]